June 29, 2017 / 7:13 AM / 2 years ago

AstraZeneca, Chi-Med take kidney cancer drug into final testing

LONDON (Reuters) - AstraZeneca and Hutchison China MediTech said on Thursday they had initiated a global late-stage clinical trial of the experimental drug savolitinib in a relatively rare type of kidney cancer.

The launch triggers a $5 million payment from AstraZeneca to the Shanghai-based drugmaker, which is listed in London and is known as Chi-Med. The move underscores Chi-Med’s drive to bring modern Chinese drugs to the international market.

The Phase III study will test savolitinib in c-MET-driven papillary renal cell carcinoma.

Reporting by Ben Hirschler, editing by David Evans

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below